文献速递药物不良反应与药物警戒

南非COVID-19疫苗免疫后不良事件信号监测系统评价

Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System.
PubMed 文献 · Drug Saf · 2025-04-16

期间37,537,009剂COVID-19疫苗报告3,846例AEFI,总体报告率10.2/10万剂。BNT162b2和Ad26.COV2.S分别获得3个和7个信号,Ad26.COV2.S增强数据另现3个信号提示掩蔽,心肌炎/心包炎为BNT162b2信号。

要点

  • 南非COVID-19疫苗AEFI总体报告率为10.2/10万剂,提示可能低报。
  • BNT162b2和Ad26.COV2.S分别检出3个和7个不成比例报告信号。
  • Ad26.COV2.S增强数据另现3个信号,提示高报告率可能掩蔽信号。

核心结论

  • 南非自发报告系统可检出COVID-19疫苗AEFI的不成比例报告信号,且信号与全球报告一致。
  • 研究提示需进一步调查低报、掩蔽及系统属性以强化监测系统。

研究设计与样本

  • 研究期间37,537,009剂COVID-19疫苗(BNT162b2和Ad26.COV2.S)接种,报告3,846例AEFI。
  • 补充分析非常规免疫规划疫苗的AEFI报告,以处理COVID-19疫苗高报告率导致的潜在信号掩蔽。

主要发现

  • 总体报告率为10.2/10万剂,Ad26.COV2.S为18.1/10万剂,BNT162b2为7.9/10万剂。
  • BNT162b2和Ad26.COV2.S分别获得3个和7个不成比例报告信号。
  • Ad26.COV2.S增强数据集另现3个AEFI信号,提示掩蔽。
  • 所有Ad26.COV2.S信号及1个BNT162b2信号见于产品信息。
  • 9个AESI中,心肌炎/心包炎为BNT162b2接种后不成比例报告信号。

临床怎么用

  • 临床药师可参考本研究信号,关注COVID-19疫苗接种后心肌炎/心包炎等AESI报告。
  • 对南非监测系统检出的信号,应结合产品信息与全球数据综合评估。
  • 需警惕低报和掩蔽现象,主动开展AEFI报告与信号验证。

局限性

  • 与其它国家比较提示存在低报。
  • 高报告率可能导致信号掩蔽,需补充分析非 routine 疫苗报告。
  • 研究基于自发报告系统,信号检测受报告质量与系统属性影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Monitoring of adverse events following immunisation (AEFI) is recommended for post-licensure surveillance. We investigated whether the South African surveillance system could detect signals of disproportionate reporting and whether these signals aligned with globally identified AEFI and adverse events of special interest (AESI) post-coronavirus disease-2019 (COVID-19) vaccination. METHODS: This retrospective pharmacovigilance study undertook disproportionality analysis of the National Department of Health AEFI database from the start of the COVID-19 vaccine rollout on 17 May 2021 to 31 December 2022. We complemented this with AEFI reports for vaccines not on the routine Expanded Programme on Immunisation schedule, to address potential masking of signals due to the high reporting rate of COVID-19 vaccine AEFI. RESULTS: During the study period, 3846 AEFI were reported for 37,537,009 doses of COVID-19 vaccines (BNT162b2 and Ad26.COV2.S) administered. The overall reporting rate was 10.2 per 100,000 doses, 18.1/100,000 and 7.9/100,000 for Ad26.COV2.S and BNT162b2, respectively. Comparison with other countries suggests underreporting. Disproportionate reporting signals were obtained for three and seven AEFI following BNT162b2 and Ad26.COV2.S vaccines, respectively. An additional three AEFI signals from Ad26.COV2.S emerged in the augmented dataset, indicating masking. All Ad26.COV2.S signals, and one BNT162b2 signal, appear in the vaccines' product information. Among nine AESI evaluated, myocarditis/pericarditis presented as a signal of disproportionate reporting following BNT162b2 vaccination. CONCLUSIONS: This study is one of the first from a lower-middle-income country, using a spontaneous reporting system for signal detection post-COVID-19 vaccination. Signals aligned with those reported globally. The study highlights the need to further investigate underreporting, masking, and system attributes for system strengthening.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Sankar C, Evans S, Meyer JC, et al. Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System. Drug Saf. 2025. PMID: 40238055. doi:10.1007/s40264-025-01547-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。